CA-AXON-NEUROSCIENCE
AXON Neuroscience presented the results of the 18 month follow-up study with an active tau vaccine at the 9th International Conference on Clinical Trials in Alzheimer’s Disease (CTAD) in San Diego (US). These results have confirmed in longer observation the encouraging phase I study results. The detailed phase I study results were published in The Lancet Neurology on December 9th 2016.
FOLLOW UP STUDY WITH THE AADVAC 1 VACCINE
The primary objective of the follow-up study was to assess the long-term safety and tolerability of AADvac1 and immunogenicity over a period of an additional 18 months. The patients received two additional AADvac1 booster vaccinations aiming to ensure persistence of induced therapeutic antibodies.
At CTAD, AXON’s Medical Director, Matej Ondrus, announced that the study confirmed overall excellent results of AADvac1 in a total treatment period of 24 months in patients with Alzheimer’s disease. Additionally, the study confirmed the ability of the booster vaccines to sustain the desired immune response. “While already in the Phase II study, AADvac1 is currently the most advanced tau disease modifying therapy in the field with the potential to be used also as a preventive treatment for AD”, said Matej Ondrus.
AADVAC1 TAU VACCINE
AADvac1 is an active tau vaccine against Alzheimer’s disease and related tauopathies. AADvac1 is designed to elicit antibodies against the pathological tau protein, which is the primary cause of neurofibrillary pathology in Alzheimer’s disease. These antibodies are expected to prevent the tau protein from pathological interactions, and thus to stop the progress of Alzheimer’s disease and neurodegeneration.
AXON NEUROSCIENCE
AXON Neuroscience is a clinical-stage biotech company developing disease-modifying therapeutics for Alzheimer's disease and other tauopathies. AXON is the first company which has successfully launched a Phase 2 study with a disease-modifying active immunotherapy against pathologically modified tau protein. The Phase 2 study is conducted in 8 European countries and has already recruited 44 out of 185 participating patients with mild AD.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161213005948/en/
Contact:
AXON Neuroscience
Andrea Becker
+421 903 576 315
media@axon-neuroscience.eu
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RTL Luxembourg Expands Deployment of Verimatrix Technologies to Protect Premier Auto Racing Against Piracy11.9.2025 17:45:00 CEST | Press release
RTL’s high-value motorsport racing content now harnesses Verimatrix Counterspy, Deepscan and Watermarking solutions to put them fully in control of their content Regulatory News: Verimatrix, (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that RTL Luxembourg, the country’s leading media company, has further expanded its use of Verimatrix anti-piracy tools to now include the full Streamkeeper suite of solutions. Initially deploying Streamkeeper Multi-DRM, RTL Luxembourg also recently implemented Counterspy, Deepscan and Watermarking solutions – the industry’s latest set of powerful tools that help further bolster proactive protections for RTL’s motorsport content revenue. It was announced in April 2024 that RTL Luxembourg selected Verimatrix Streamkeeper Multi-DRM to ensure that RTL Luxembourg remained in full control of its valuable digital assets while also consistently keeping costs low and preventing unneeded technical com
Xylem and Amazon Partner on Smart Water Upgrades to Save More Than 1.3 Billion Liters Annually in Mexico11.9.2025 16:00:00 CEST | Press release
Advanced water technology helps Mexico City and Monterrey reduce leaks and improve supply for thousands of residents Residents in Mexico City and Monterrey will soon enjoy more reliable water supply as the two cities launch groundbreaking infrastructure upgrades to save over 1.3 billion liters of water a year – easing pressure from the rapid urbanization and persistent drought conditions that have strained local water systems. The two cities are working in partnership with global water technology company Xylem (NYSE: XYL) and Amazon (NASDAQ: AMZN) to deploy Xylem Vue, an advanced software platform that applies data and analytics to detect leaks, cut water losses and improve residents’ water supply. The projects are estimated to save upwards of 800 million liters of water a year in Mexico City and 560 million liters a year in Monterrey. “In a water-stressed region, where every liter counts, recovering more than a billion liters of water each year is a game-changer,” said Jaime Barba, Ge
HTEC Partners with World Economic Forum11.9.2025 15:56:00 CEST | Press release
HTEC to bring AI expertise to contribute toindustry transformation and real-world outcomes HTEC, a global digital engineering and product development company, has today announced that it has joined the World Economic Forum’s (WEF) Centre for AI Excellence. HTEC will contribute to the community through its expertise and thought leadership to help advance AI adoption and AI innovation across its core industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911910448/en/ HTEC Partners with World Economic Forum to bring AI expertise to help with industry transformation and real-world outcomes WEF’s Centre for AI Excellence is bringing together leading industry organisations and experts to work together to advance the pace and positive impact AI can have in economies and societies. Its goal is to unlock transformative potential in an equitable and human-centered way, which is well aligned with HTEC’s principles and values. A
Alipay Tap! Users Reach 200 Million, Expands to Over 1,000 Scenarios Beyond Payments11.9.2025 15:31:00 CEST | Press release
Alipay Tap! now supports over 1,000 everyday scenarios, making payments and customer interactions faster and simpler with just a tap.The company also launched its first AI-powered payment service in Luckin Coffee’s app, enabling hassle-free ordering and payment via voice commands to AI agents for the first time. Alipay announced today at the 2025 INCLUSION · Conference on the Bund in Shanghai that its QR code-based contactless payment and engagement solution, Alipay Tap!, has rapidly grown its user base to 200 million since its launch in China in June 2024. The milestone comes just months after surpassing 100 million users in April 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911881010/en/ With Alipay Tap!, users can open a vending machine with a simple tap Designed to be simpler than QR code scanning, Alipay Tap! lets users complete a transaction or access a service by simply tapping their unlocked phone on a mer
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis11.9.2025 15:05:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey Clinical Medical Research Award for his role “in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease.” Dr. Negulescu is one of three awardees, alongside Jesús (Tito) González, a former Vertex scientist, and Michael Welsh, Professor of Internal Medicine-Pulmonary, Critical Care and Occupational Medicine, University of Iowa. The prize honors the groundbreaking work of Dr. Negulescu, Dr. González and the entire Vertex team who discovered and developed the first and only approved medicines that address the underlying cause of CF. To date, Vertex has brought five transformational medicines to patients with CF which have fundamentally changed the way this disease is treated. “I’m hon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom